Evidence map›Paper›PMID 40917863›Full record

ArticleFrontiers in medicine2025

Adding pegylated interferon-α to nucleos(t)ide analogs improves HBsAg clearance in chronic hepatitis B with low-level viremia.

Lilin Wang, Junfeng Lu, Dan Liu, Shan Ren, Xinyue Chen, Zhongjie Hu, Sujun Zheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lilin WangThe First Department of Liver Disease Center, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Junfeng LuThe First Department of Liver Disease Center, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Dan LiuThe First Department of Liver Disease Center, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Shan RenThe First Department of Liver Disease Center, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Xinyue ChenThe First Department of Liver Disease Center, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Zhongjie HuThe First Department of Liver Disease Center, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Sujun ZhengThe First Department of Liver Disease Center, Beijing You'an Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Low-level viremia (LLV) is associated with the progression of liver fibrosis and a high risk of hepatocellular carcinoma in patients with chronic hepatitis B (CHB). The present study aimed to compare the efficacy between nucleos(t)ide analogs (NAs) therapy and combination therapy of NAs and pegylated interferon-α (pegIFN-α) in entecavir (ETV)-treated CHB patients with LLV. Methods: This was a retrospective cohort study. ETV-treated CHB patients with LLV were included and divided into the NA group and the NA+IFN group. The NA group comprised patients switching to tenofovir alafenamide fumarate, whereas the NA+IFN group comprised those adding on pegIFN-α additionally. We compared changes in HBV markers and complete virological response (CVR) between the two groups. Results: A total of 127 patients were enrolled, including 51 in NA+IFN group and 76 in NA group. In the NA+IFN group, the decline in HBsAg level from baseline (△ HBsAg) was significantly greater (-0.17 log Conclusion: In ETV-treated patients with LLV, receiving NAs plus pegIFN-α tends to increase the effect of HBsAg clearance.

Indexed as

chronic hepatitis BHBsAg clearancelow-level viremiapegylated interferon-αtenofovir alafenamide fumarate

Identifiers

PMID40917863
PMCPMC12411537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.